The current price-to-earnings ratio of LXRX can't be determined, as the TTM EPS of -$0.75 is negative. The most recent PE ratio recorded for Lexicon Pharmaceuticals was 9.98 in June 2021.
Over the last six years, the average PE ratio of Lexicon Pharmaceuticals has been 4.63. In the past six years, LXRX's PE ratio was at its highest in the Jun 2021 quarter at 9.98, with a price of $4.59 and an EPS of $0.46. The Sep 2019 quarter recorded the bottom point at 1.95, with a price of $3.01 and an EPS of $1.54.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | 3.37 | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
REGN Regeneron Pharmaceuticals Inc | 16.23 | $77.13B |
TMO Thermo Fisher Scientific Inc | 32.77 | $200.45B |
BMRN Biomarin Pharmaceutical Inc | 38.62 | $12.51B |
LGND Ligand Pharmaceuticals Inc | 43.42 | $2.17B |
RARE Ultragenyx Pharmaceutical Inc | N/A | $4.08B |
ILMN Illumina Inc | N/A | $21.57B |
ESPR Esperion Therapeutics Inc | N/A | $431.51M |
LXRX Lexicon Pharmaceuticals Inc | N/A | $258.36M |
The current price to earnings ratio of LXRX can't be calculated, as its EPS of -$0.75 is negative.
The highest quarterly PE ratio in the last six years has been 9.98 and it was in the Jun 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.